AbbVie’s Rinvoq passes PhIII AD test; Dicerna races Alnylam; New Sarepta gene & cell collab
→ Almost a year after it was approved for rheumatoid arthritis, AbbVie’s JAK inhibitor Rinvoq was shown for the first time to work as a monotherapy in atopic dermatitis. In a Phase III study, two different doses of the drug beat placebo on all primary and secondary endpoints. Of patients in the high dose group, 80% saw at least 75% skin clearance versus 16% for placebo. That number was 70% in the low dose group.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.